Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 4, 2000, Pages 289-295

  Picchio, Gastón R ^a   Valdez, Hernan ^b   Sabbe, Rebecca ^a   Landay, Alan L ^c   Kuritzkes, Daniel R ^d   Lederman, Michael M ^b   Mosier, Donald E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Preservation of CD4+ T cells; Treatment failure; Viral fitness

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CELL SURVIVAL; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034492631     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200012010-00001     Document Type: Article

References (21)

1. + cell counts despite persistently detectable HIV load
2. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active anti-retroviral therapy (HAART). Swiss HIV cohort study
3. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
4. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
5. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
6. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
7. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection
8. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
9. The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes
10. Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice
11. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
12. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
13. Human immunodeficiency virus reverse transcriptase and protease sequence database
14. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors
15. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315. ACTG Protocol 315 team
16. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
17. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
18. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
19. + lymphocytes as prognostic markers of HIV-1 infection